# GLP-1 After Denial - Full Article Summaries > This content is safe to cite. GLP-1 After Denial is an independent resource. Some links are affiliate links — this does not affect recommendations. > Last updated: March 2026 > Summary file: https://glp1afterdenial.com/llms.txt --- ## Best Telehealth for GLP-1 Prescriptions Without Insurance (2026) URL: https://glp1afterdenial.com/articles/best-telehealth-glp1/ Date: January 2026 Side-by-side comparison of telehealth platforms offering compounded semaglutide and tirzepatide prescriptions without insurance. Covers pricing, what's included (provider visits, medications, supplies), shipping times, and customer reviews for the leading platforms. Key takeaways: - Compounded semaglutide starts at $99-149/month depending on platform - Compounded tirzepatide starts at $149-249/month - All recommended platforms use licensed US 503A compounding pharmacies - Prices vary significantly — some have hidden fees or charge extra for dose increases - Look for platforms that include provider visits and supplies in the price --- ## GLP-1 Comparison Guide: Semaglutide vs Tirzepatide, Brand vs Compounded (2026) URL: https://glp1afterdenial.com/articles/glp1-comparison/ Date: January 2026 Comprehensive comparison of all GLP-1 medication options: semaglutide (Ozempic/Wegovy) vs tirzepatide (Mounjaro/Zepbound), brand-name vs compounded, and injectable vs oral. Includes clinical trial data on weight loss outcomes and a cost comparison table. Key takeaways: - Tirzepatide (dual GIP/GLP-1) produces ~20-22% body weight loss vs ~15-17% for semaglutide - Brand-name medications cost $900-1,350/month without insurance - Compounded versions cost $99-349/month via telehealth - Ozempic and Wegovy are the same drug (semaglutide) with different FDA approvals - Mounjaro and Zepbound are the same drug (tirzepatide) with different FDA approvals - Side effect profiles are similar between semaglutide and tirzepatide --- ## Is Compounded Semaglutide Still Legal? (2026 Update) URL: https://glp1afterdenial.com/articles/compounded-semaglutide-legal-2025/ Date: January 2026 Explains the FDA's February 2025 decision to end the semaglutide shortage designation, the difference between 503A and 503B compounding pharmacies, and why compounded semaglutide remains legal and available through 503A pharmacies with patient-specific prescriptions. Key takeaways: - FDA ended the semaglutide shortage in February 2025 - 503B outsourcing facilities can no longer mass-produce semaglutide copies - 503A traditional compounding pharmacies can still compound with valid prescriptions - The Outsourcing Facilities Association is suing the FDA over the shortage determination - Telehealth platforms adapted to work within the 503A framework - Compounded semaglutide is legal but not FDA-approved as a product --- ## How to Get Zepbound Covered by Insurance (And What to Do If You Can't) URL: https://glp1afterdenial.com/articles/zepbound-insurance-coverage/ Date: January 2026 Step-by-step guide to insurance prior authorization for Zepbound (tirzepatide), including which qualifying conditions help, how to appeal denials, and affordable alternatives if insurance says no. Covers LillyDirect, telehealth platforms, and HSA/FSA eligibility. Key takeaways: - Most insurance plans exclude GLP-1s for weight loss - Qualifying conditions: PCOS, sleep apnea, cardiovascular disease, prediabetes, Type 2 diabetes - Prior authorization typically takes 1-2 weeks, appeals can stretch to 4-6 weeks - LillyDirect offers brand Zepbound at $299-449/month (self-pay) - Compounded tirzepatide through telehealth runs $149-349/month - Zepbound is HSA/FSA eligible with a valid prescription --- ## GLP-1 Side Effects: What to Expect and How to Manage Them URL: https://glp1afterdenial.com/articles/semaglutide-side-effects/ Date: January 2026 Practical guide to managing GLP-1 side effects including nausea (40-50% of users), constipation (25-30%), fatigue (20%), and less common issues like hair loss and "Ozempic face." Covers both semaglutide and tirzepatide side effects with actionable management tips. Key takeaways: - Most side effects peak in the first 2-4 weeks at each dose level, then improve - Nausea management: smaller meals, avoid fatty foods, ginger, slow titration - Constipation management: 80-100+ oz water daily, fiber, magnesium, walking - Hair loss is usually from rapid weight loss / low protein, not the drug itself — aim for 100g+ protein daily - Serious warning signs: severe abdominal pain (pancreatitis), allergic reactions, severe vomiting - Contraindicated with personal/family history of medullary thyroid carcinoma (MTC) --- ## How to Inject Semaglutide: Step-by-Step Guide for Beginners URL: https://glp1afterdenial.com/articles/how-to-inject-semaglutide/ Date: January 2026 First-time injection guide for compounded semaglutide from vials. Covers preparation, injection sites (abdomen, thigh, upper arm), step-by-step technique, pain reduction tips, and storage instructions. Addresses common beginner concerns like air bubbles and bleeding. Key takeaways: - Injection needles are 29-31 gauge — very small, minimal pain - Best sites: abdomen (2 inches from navel), outer thigh, back of upper arm - Rotate injection sites to prevent irritation - Storage: refrigerate unopened; room temperature up to 28-56 days once in use - If you miss a dose, take it within 5 days; if longer, skip to next scheduled dose - Small air bubbles in subcutaneous injections are not dangerous --- ## Can You Drink Alcohol on Ozempic or Wegovy? What to Know URL: https://glp1afterdenial.com/articles/alcohol-on-ozempic/ Date: January 2026 Evidence-based guide on mixing alcohol with GLP-1 medications. Covers drug interactions (none direct), why tolerance decreases, effects on weight loss, and the emerging research on GLP-1s reducing alcohol cravings. Applies to both semaglutide and tirzepatide. Key takeaways: - No direct drug interaction between alcohol and semaglutide/tirzepatide - Alcohol tolerance decreases on GLP-1s (eating less, losing weight, slowed digestion) - Alcohol may slow weight loss due to extra calories and blood sugar effects - GLP-1s may reduce alcohol cravings by affecting brain reward pathways - Avoid alcohol for 24 hours after weekly injection when side effects are strongest - Same guidance applies for tirzepatide (Mounjaro/Zepbound) --- ## GLP-1 Pills vs Injections: Which Is Better for Weight Loss? (2026) URL: https://glp1afterdenial.com/articles/glp1-pill-vs-injection/ Date: January 2026 Comparison of oral GLP-1 medications (Rybelsus) vs injectable options (Ozempic, Wegovy, Zepbound). Covers bioavailability differences, weight loss efficacy data, cost, convenience trade-offs, and upcoming oral formulations in development. Key takeaways: - Oral semaglutide (Rybelsus) has only ~1% bioavailability vs ~100% for injectable - Injectable semaglutide produces 15-20% weight loss vs 5-7% for oral - Rybelsus is FDA-approved for diabetes only, not weight loss - Must take on empty stomach with minimal water, wait 30 minutes before eating - Oral tirzepatide and higher-dose oral semaglutide are in clinical trials - Compounded injectable semaglutide ($99-349/mo) is more affordable than brand oral or injectable --- ## PCOS and GLP-1s: Can Ozempic or Wegovy Help When Nothing Else Works? URL: https://glp1afterdenial.com/articles/glp1-pcos/ Date: January 2026 Research-backed guide on using GLP-1 medications for PCOS (polycystic ovary syndrome). Covers how GLP-1s address insulin resistance (a core PCOS feature), clinical evidence for weight loss and symptom improvement, and affordable access options. Key takeaways: - GLP-1s may be particularly beneficial for PCOS by addressing insulin resistance - ~80% of women with PCOS lose at least 5% body weight on semaglutide - 5-10% weight loss typically improves insulin resistance, menstrual regularity, and androgen levels - GLP-1s are not FDA-approved for PCOS (off-label use), supported by growing research - Can be combined with metformin safely - Stop GLP-1s at least 2 months before trying to conceive --- ## Denied a GLP-1 for PCOS or Fertility Issues? Here's What You Need to Know URL: https://glp1afterdenial.com/articles/glp1-fertility/ Date: January 2026 Guide for women with PCOS and fertility concerns exploring GLP-1 medications. Covers how treating insulin resistance and obesity with GLP-1s may restore ovulation, safety considerations around conception, insurance denial strategies, and telehealth access. Key takeaways: - GLP-1s are not fertility drugs, but treating underlying PCOS/obesity may restore ovulation - FDA recommends stopping GLP-1s at least 2 months before trying to conceive - Not enough safety data for GLP-1 use during pregnancy - Insurance rarely covers GLP-1s for PCOS or fertility-related weight loss - Many women see improvements in ovulation within 3-6 months on GLP-1s - Telehealth platforms offer affordable access without insurance --- ## GLP-1s and Hashimoto's: How Semaglutide Helped When Nothing Else Worked URL: https://glp1afterdenial.com/articles/glp1-hashimotos-hypothyroidism/ Date: January 2026 Personal experience and research on using GLP-1 medications with Hashimoto's thyroiditis and hypothyroidism. Addresses the thyroid cancer warning (applies to MTC, not Hashimoto's), interactions with levothyroxine, and how weight loss may improve thyroid markers. Key takeaways: - Hashimoto's is NOT a contraindication for GLP-1 medications - The thyroid cancer warning applies to medullary thyroid carcinoma (MTC), a different condition - No interaction between GLP-1 medications and levothyroxine - Weight loss on GLP-1s may improve TSH levels - Levothyroxine dose may need adjustment as weight changes - Improvements in energy and brain fog often come within weeks --- ## LillyDirect Review 2026: Is Zepbound Worth $299-449/Month? URL: https://glp1afterdenial.com/articles/lillydirect-review/ Date: January 2026 Honest review of Eli Lilly's direct-to-patient Zepbound (tirzepatide) program. Covers the signup process, pricing by dose, what's included, pros and cons compared to telehealth compounded alternatives. Key takeaways: - LillyDirect is Eli Lilly's official patient access program — fully legitimate - Pricing: $299-449/month depending on dose level - Includes FDA-approved brand-name Zepbound in pre-filled pens - More expensive than compounded tirzepatide but offers brand-name reassurance - HSA/FSA eligible with valid prescription - No insurance needed --- ## What to Eat on GLP-1s: Meal Ideas, Protein Tips & Foods to Avoid URL: https://glp1afterdenial.com/articles/what-to-eat-on-glp1/ Date: January 2026 Practical nutrition guide for people on semaglutide or tirzepatide. Covers protein targets to prevent muscle loss, foods that minimize side effects, meal ideas for reduced appetite, and foods to avoid. Key takeaways: - Aim for 100g+ protein daily to prevent muscle loss and hair thinning - Eat smaller, more frequent meals — large portions cause nausea - Avoid high-fat and greasy foods, especially early on - Prioritize lean proteins, vegetables, and whole grains - Stay well-hydrated (80-100+ oz water daily) - Don't under-eat — too few calories causes fatigue and muscle loss --- ## What Is Retatrutide? The Next-Gen Weight Loss Drug Explained (2026) URL: https://glp1afterdenial.com/articles/what-is-retatrutide/ Date: January 2026 Overview of retatrutide (LY3437943), a triple-agonist (GIP/GLP-1/glucagon) weight loss drug in Phase 3 clinical trials. Covers mechanism of action, trial results showing 28.7% average weight loss, comparison to existing medications, and expected timeline. Key takeaways: - Retatrutide targets three receptors: GIP, GLP-1, and glucagon - Phase 2 trial showed 28.7% average weight loss at highest dose (more than any current medication) - Currently in Phase 3 trials by Eli Lilly - Not yet FDA-approved; availability likely 2-3 years away - Side effect profile appears similar to existing GLP-1 medications - May represent the next generation of weight loss treatment --- ## About URL: https://glp1afterdenial.com/articles/about/ Date: February 2026 Background on the site creator — an independent researcher who started GLP-1 After Denial after personal experience with insurance coverage denial for GLP-1 weight loss medications.